Anti-MLKL antibody [EPR17514],Abcam,AB184718
Product Specifications Anti-MLKL antibody [EPR17514] (ab184718) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in ICC/IF, IHC-P, WB in human samples. Anti-MLKL antibody [EPR17514] (ab184718) specifically detects MLKL (UniProt ID: Q8NB16; Molecular weight: 54kDa) and is sold in 100 µL and 1 mL selling sizes. Quality and Validation Abcam's high quality manufacturing and validation processes ensure Anti-MLKL antibody [EPR17514] (ab184718) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. The specificity of Anti-MLKL antibody [EPR17514] (ab184718) has been confirmed by testing in knockout samples. Anti-MLKL antibody [EPR17514] (ab184718) has been cited over 84 times in peer reviewed journals and is trusted by the scientific community. Anti-MLKL antibody [EPR17514] (ab184718) has 5 independent reviews from customers. Related Products Conjugation-ready, carrier free format available for antibody clone EPR17514 - ab211045 . Antibody clone EPR17514 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor® 488, Alexa Fluor® 647, Alexa Fluor® 594 ( ab207901 , ab207902 , ab208082 ). Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .
Host
Rabbit
Reactivity
Human
Application
ICC/IF, IHC-P, WB
Platform ID
BAB886608690
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Pseudokinase that plays a key role in TNF-induced necroptosis, a programmed cell death process (PubMed : 22265413, PubMed : 22265414, PubMed : 22421439, PubMed : 24316671). Does not have protein kinase activity (PubMed : 22265413, PubMed : 22265414, PubMed : 22421439, PubMed : 24316671). Activated following phosphorylation by RIPK3, leading to homotrimerization, localization to the plasma membrane and execution of programmed necrosis characterized by calcium influx and plasma membrane damage (PubMed : 22265413, PubMed : 22265414, PubMed : 22421439, PubMed : 24316671). In addition to TNF-induced necroptosis, necroptosis can also take place in the nucleus in response to orthomyxoviruses infection : following activation by ZBP1, MLKL is phosphorylated by RIPK3 in the nucleus, triggering disruption of the nuclear envelope and leakage of cellular DNA into the cytosol.following ZBP1 activation, which senses double-stranded Z-RNA structures, nuclear RIPK3 catalyzes phosphorylation and activation of MLKL, promoting disruption of the nuclear envelope and leakage of cellular DNA into the cytosol (By similarity). Binds to highly phosphorylated inositol phosphates such as inositolhexakisphosphate (InsP6) which is essential for its necroptotic function (PubMed : 29883610). See full target information MLKL
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
- Products>Trial Size Antibodies
Please provide the required information below so that we can quickly source your products.